CEO Statement

Motivated by the prospect of better patient health, Corline Biomedical focuses on anti-thrombotic and anti-inflammatory solutions in areas with significant unmet clinical needs.

We are proud to say that for a multitude of clinically critical applications we are starting to see strong support by scientific data that the Corline heparin technology - CHC™ - maintains its best-in-class anti-thrombotic properties as a medical device coating, offers protective effects against unwanted immune responses associated with transplantation and cell therapies, and that it is also beneficial for the engraftment response. It is clear that patient recovery may be improved in a multitude of clinical situations.

In addition to our high-growth business within the medical device industry, where our proprietary surface coating CHS™ is used to enable clinically significant innovation in neurovascular, structural heart and peripheral vascular applications, we note increased interest for partnering opportunities vis-a-vis our regenerative medicine pipeline, with Renaparin^® for the use in kidney transplantation and as a functional addition to a number of tissue-based partner products.

Corline’s commitment to true innovation is fueled by our highly skilled people and an active network of frontline research professionals. We hope that our high-striving commitment to “solution-finding” is visible throughout our website.

Welcome, and thank you for your interest in Corline!

Henrik Nittmar
Chief Executive Officer